Cargando…

Fabry disease – a multisystemic disease with gastrointestinal manifestations

Nonspecific gastrointestinal (GI) symptoms, such as postprandial cramping pain, diarrhea, nausea and vomiting are typical symptoms for irritable bowel syndrome or inflammatory bowel disease, but may also be the first symptoms of Fabry disease (FD). This review focus on GI manifestations in FD, by pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenders, Malte, Brand, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803088/
https://www.ncbi.nlm.nih.gov/pubmed/35090382
http://dx.doi.org/10.1080/19490976.2022.2027852
_version_ 1784642795237015552
author Lenders, Malte
Brand, Eva
author_facet Lenders, Malte
Brand, Eva
author_sort Lenders, Malte
collection PubMed
description Nonspecific gastrointestinal (GI) symptoms, such as postprandial cramping pain, diarrhea, nausea and vomiting are typical symptoms for irritable bowel syndrome or inflammatory bowel disease, but may also be the first symptoms of Fabry disease (FD). This review focus on GI manifestations in FD, by providing an overview of symptoms, a proper diagnosis, an appropriate management by FD-specific and concomitant medications and lifestyle interventions. We provide comprehensive literature-based data combined with personal experience in the management of FD patients. Since FD is rare and the clinical phenotype is heterogeneous, affected patients are often misdiagnosed. Consequently, physicians should consider FD as a possible differential diagnosis when assessing unspecific GI symptoms. Improved diagnostic tools, such as a modified GI symptom assessment scale can facilitate the diagnosis of FD in patients with GI symptoms of unknown cause and thus enable the timely initiation of a disease-specific therapy. Expansive intravenous enzyme replacement therapy with α-galactosidase A or oral chaperone therapy for patients with amenable mutations improve the disease burden including GI symptoms, but a timely start of therapy is crucial for the prognosis. A special diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) or pro- and prebiotics might improve FD-typical GI symptoms. Furthermore, preliminary success was reported with the oral administration of α-galactosidase A. In addition to a timely initiation of FD-specific therapy, affected patients with GI symptoms might benefit from a FODMAP-low diet, pro- and prebiotics and/or low-cost oral substitution with AGAL to support digestion and reduce dysbiosis.
format Online
Article
Text
id pubmed-8803088
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-88030882022-02-01 Fabry disease – a multisystemic disease with gastrointestinal manifestations Lenders, Malte Brand, Eva Gut Microbes Review Nonspecific gastrointestinal (GI) symptoms, such as postprandial cramping pain, diarrhea, nausea and vomiting are typical symptoms for irritable bowel syndrome or inflammatory bowel disease, but may also be the first symptoms of Fabry disease (FD). This review focus on GI manifestations in FD, by providing an overview of symptoms, a proper diagnosis, an appropriate management by FD-specific and concomitant medications and lifestyle interventions. We provide comprehensive literature-based data combined with personal experience in the management of FD patients. Since FD is rare and the clinical phenotype is heterogeneous, affected patients are often misdiagnosed. Consequently, physicians should consider FD as a possible differential diagnosis when assessing unspecific GI symptoms. Improved diagnostic tools, such as a modified GI symptom assessment scale can facilitate the diagnosis of FD in patients with GI symptoms of unknown cause and thus enable the timely initiation of a disease-specific therapy. Expansive intravenous enzyme replacement therapy with α-galactosidase A or oral chaperone therapy for patients with amenable mutations improve the disease burden including GI symptoms, but a timely start of therapy is crucial for the prognosis. A special diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) or pro- and prebiotics might improve FD-typical GI symptoms. Furthermore, preliminary success was reported with the oral administration of α-galactosidase A. In addition to a timely initiation of FD-specific therapy, affected patients with GI symptoms might benefit from a FODMAP-low diet, pro- and prebiotics and/or low-cost oral substitution with AGAL to support digestion and reduce dysbiosis. Taylor & Francis 2022-01-28 /pmc/articles/PMC8803088/ /pubmed/35090382 http://dx.doi.org/10.1080/19490976.2022.2027852 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Lenders, Malte
Brand, Eva
Fabry disease – a multisystemic disease with gastrointestinal manifestations
title Fabry disease – a multisystemic disease with gastrointestinal manifestations
title_full Fabry disease – a multisystemic disease with gastrointestinal manifestations
title_fullStr Fabry disease – a multisystemic disease with gastrointestinal manifestations
title_full_unstemmed Fabry disease – a multisystemic disease with gastrointestinal manifestations
title_short Fabry disease – a multisystemic disease with gastrointestinal manifestations
title_sort fabry disease – a multisystemic disease with gastrointestinal manifestations
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803088/
https://www.ncbi.nlm.nih.gov/pubmed/35090382
http://dx.doi.org/10.1080/19490976.2022.2027852
work_keys_str_mv AT lendersmalte fabrydiseaseamultisystemicdiseasewithgastrointestinalmanifestations
AT brandeva fabrydiseaseamultisystemicdiseasewithgastrointestinalmanifestations